COMPANY

Novelmed Therapeutics Inc

HQ: Cleveland, OH source · novelmed.com ↗ · Midwest

NovelMed Therapeutics is a biotechnology company. From company website Source · Oct 12, 2026

Keywords: biotechnology therapeutics macular degeneration rheumatoid arthritis arthritis Paroxysmal Nocturnal Hemoglobinuria wet amd geographic atrophy C3 Glomerulopathy IgA Nephropathy aHUS - Atypical Hemolytic Uremic Syndrome PNH - Paroxysmal Nocturnal Hemoglobinuria Dermatomyositis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis myelitis NM8074

Profile checked Oct 10, 2026

9Trials (company is sponsor)41NIH grants

Timeline

2028-02 Trial start Phase 2: Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) source ↗
2027-11 Trial start Phase 2: Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy source ↗
2027-05 Trial start Phase 1/Phase 2: Study of NM8074 in Adult C3 Glomerulopathy Patients source ↗
2027-01 Trial start Phase 2: Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris source ↗
2026-06 Trial start Phase 2: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) source ↗
2026-06 Trial start Phase 2: Study of NM8074 in Patients with Dermatomyositis (DM) source ↗
2026-06 Trial start Phase 2: Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) source ↗
2026-04 Trial start Phase 2: Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy source ↗
Aug 12, 2020 Trial start Phase 1: First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers source ↗

Upcoming milestones

2027-08 (ESTIMATED) · Phase 2 · Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy · NCT05646524
2027-09 (ESTIMATED) · Phase 2 · Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · NCT05731050
2027-10 (ESTIMATED) · Phase 2 · Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) · NCT06226662
2027-11 (ESTIMATED) · Phase 2 · Study of NM8074 in Patients with Dermatomyositis (DM) · NCT06887738
2029-07 (ESTIMATED) · Phase 2 · Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris · NCT05646563
2029-08 (ESTIMATED) · Phase 1/Phase 2 · Study of NM8074 in Adult C3 Glomerulopathy Patients · NCT05647811
2030-04 (ESTIMATED) · Phase 2 · Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy · NCT05684159
2030-12 (ESTIMATED) · Phase 2 · Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) · NCT06454110

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT05647811	Study of NM8074 in Adult C3 Glomerulopathy Patients	Phase 1/Phase 2	Not yet recruiting	2027-05	2029-08 (estimated)
NCT05646563	Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris	Phase 2	Not yet recruiting	2027-01	2029-07 (estimated)
NCT06454110	Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)	Phase 2	Not yet recruiting	2028-02	2030-12 (estimated)
NCT05684159	Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy	Phase 2	Not yet recruiting	2027-11	2030-04 (estimated)
NCT05731050	Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 2	Not yet recruiting	2026-06	2027-09 (estimated)
NCT06887738	Study of NM8074 in Patients with Dermatomyositis (DM)	Phase 2	Not yet recruiting	2026-06	2027-11 (estimated)
NCT05646524	Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy	Phase 2	Not yet recruiting	2026-04	2027-08 (estimated)
NCT06226662	Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)	Phase 2	Not yet recruiting	2026-06	2027-10 (estimated)
NCT05642546	First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers	Phase 1	Completed	Aug 12, 2020	Jun 15, 2022 (actual)

NIH awards 41

Annual award amounts. Total $19.8M.

Jul 9, 2021 NIH award 1R44HL156774-01A1 FY2021: $533,165 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Disease Modifying Treatment for Hemo source ↗
Jun 1, 2021 NIH award 1R44AG072939-01 FY2021: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Treatment of Complement-Mediated Myeli source ↗
Feb 28, 2017 NIH award 5R44HL122028-03 FY2017: $1,277,607 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Preclinical and Clinical Evaluation source ↗
Sep 15, 2015 NIH award 3R44EY024809-01S1 FY2015: $39,400 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Single Therapy for Wet AMD & Geograph source ↗
Sep 4, 2015 NIH award 5R44DK082025-03 FY2015: $601,912 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Novel Treatments to Abolish Inflammato source ↗
Mar 20, 2015 NIH award 4R44HL122028-02 FY2015: $1,159,286 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Preclinical and Clinical Evaluation source ↗
Sep 15, 2014 NIH award 1R44EY024809-01 FY2014: $548,724 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Single Therapy for Wet AMD & Geographi source ↗
Aug 26, 2014 NIH award 3R44EY019191-03S2 FY2014: $25,000 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors for Macular Deg source ↗
Aug 1, 2014 NIH award 4R44HL115909-02 FY2014: $889,438 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Alternative Pathway Inhibitors for Orp source ↗
Jul 23, 2014 NIH award 2R44DK082025-02A1 FY2014: $849,661 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Novel Treatments to Abolish Inflamma source ↗
Mar 28, 2014 NIH award 3R44EY019191-03S1 FY2014: $239,000 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors for Macular De source ↗
Feb 21, 2014 NIH award 1R44HL122028-01 FY2014: $467,832 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Preclinical and Clinical Evaluation of source ↗
Sep 10, 2013 NIH award 3R44AG041564-02S1 FY2013: $78,750 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors as DMOADs source ↗
Aug 6, 2013 NIH award 4R44AG041564-02 FY2013: $307,870 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors as DMOADs source ↗
Aug 1, 2013 NIH award 1R44HL115909-01A1 FY2013: $542,572 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Alternative Pathway Inhibitors for O source ↗
Jul 11, 2013 NIH award 5R44EY019191-03 FY2013: $597,897 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors for Macular Dege source ↗
Aug 7, 2012 NIH award 5R44HL102890-03 FY2012: $691,377 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Inhibition of Cardiac Device Induced C source ↗
Jul 17, 2012 NIH award 1R44AG041564-01 FY2012: $294,766 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors as DMOADs source ↗
Jul 16, 2012 NIH award 2R44EY019191-02A1 FY2012: $466,354 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors for Macular De source ↗
Jul 12, 2012 NIH award 5R44HL099015-03 FY2012: $633,313 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Controlling Inflammation Due to Cardia source ↗
Mar 30, 2012 NIH award 5R44AG039118-03 FY2012: $968,470 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Disease Modifying Biologics for Rheuma source ↗
Aug 18, 2011 NIH award 4R44HL102890-02 FY2011: $503,352 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Inhibition of Cardiac Device Induced C source ↗
Jul 30, 2011 NIH award 4R44HL099015-02 FY2011: $719,654 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Controlling Inflammation Due to Cardia source ↗
Apr 8, 2011 NIH award 4R44AG039118-02 FY2011: $929,079 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Disease Modifying Biologics for Rheuma source ↗
Sep 13, 2010 NIH award 1R43GM090341-01A1 FY2010: $266,001 awarded for that fiscal year; activity R43 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Device for Surgical Adhesion Prevent source ↗
Aug 17, 2010 NIH award 1R44HL102890-01A1 FY2010: $516,118 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Inhibition of Cardiac Device Induced source ↗
Aug 9, 2010 NIH award 1R43AI085697-01 FY2010: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Neutralizing Antibodies for Complement source ↗
Jul 30, 2010 NIH award 1R44AG039118-01A1 FY2010: $791,681 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Disease Modifying Biologics for Rheu source ↗
Apr 26, 2010 NIH award 1R44HL099015-01 FY2010: $420,195 awarded for that fiscal year; activity R44 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Controlling Inflammation Due to Cardia source ↗
Sep 18, 2009 NIH award 3R43EY019191-01A1S1 FY2009: $31,982 awarded for that fiscal year; activity R43 (SBIR); PI BANSAL, REKHA; recipient as written: NOVELMED THERAPEUTICS, INC., CLEVELAND, OH. Complement Inhibitors for Macular D source ↗

Connect

Contact page